Hainan Manaslu Acquisition Corp. (NASDAQ:HMAC) announced in an 8-K this afternoon that its shareholders approved its combination with brand management company Able View at a special meeting held on August 2.
At the meeting, there were 7,295,963 ordinary shares representing approximately 81.37% of the issued and outstanding ordinary shares present, constituting a quorum.
The deal received overwhelming approval with holders representing 7,003,776 shares voting in favor of the business combination, while holders of only 292,187 shares voted against it.
In connection with the shareholders’ vote at the meeting, 6,766,651 ordinary shares were tendered for redemption, representing 98.07% of HMAC’s trust. The SPAC is now left with $1.38 million following the vote.
Nonetheless, Hainan Manaslu plans to close the business combination as soon as possible and will continue to accept reversal of redemption requests until closing. Once the deal is completed, the combined company is expected to trade on the Nasdaq.
The SPAC inked its $400 million business combination with Able View in November 2022. Shanghai-based Able View is a cross-border brand management company focusing on beauty and personal care segments.
All other proposals on the ballot, including the NTA Requirement Amendment Proposal, the Charter Proposal, and the Equity Incentive Plan Proposal, were also approved with minimal pushback from shareholders.
Terms Tracker for the Week Ending October 25, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Finally, a little more SPAC action this week with no less than four IPOs priced. That brings October’s tally to seven IPOs with one more...
At the SPAC of Dawn The rebound of the growth companies that made up the SPAC class of 2021 has been one of the bigger stories of second half of 2024, but not all of the de-SPACs are feeling the love equally. Instead, in many new sectors that hit the public markets together as a...
DT Cloud (NASDAQ:DYCQ) has entered into a definitive agreement to combine with Maius Pharmaceutical at an equity value of $250 million. Shanghai-based Maius is a drug developer and researcher focused on small-molecule chemical treatments for different forms of cancer. The combined company is expected to trade on the Nasdaq once the deal is completed in...
Charlton Aria Acquisition Corporation announced the pricing of its $75 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “CHARU”, Thursday, October 24, 2024. The new SPAC plans to focus on industries that complement the management team’s and board of director’s background and network. The sponsor team for...
At the SPAC of Dawn As the market goes through a cooling period this week, new readouts for jobless claims and new home sales are set to hit later today. Jobless claims are of course something of a proxy indicator for SPACs as to when the Fed might continue to its rate-cutting process, while home...